AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30768407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline for 12 weeks
Number of subjects: 14
Study 30768407 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 14
Study 30768407 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 14
Study 30768457 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 263
Study 30768457 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia (Control)
Number of subjects: 263
Study 30768838 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir/grazoprevir treatment after recipient HCV was first detected
Number of subjects: 10
Study 30768838 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-infected hearts transplantation
Number of subjects: 10
Study 30769292 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mould infections (IMIs)
Number of subjects: 398
Study 30770054 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time surgery
Number of subjects: 9861
Study 30770207 — intervention group
Group type: EXPERIMENTAL
Intervention: Goals-of-care conversations
Number of subjects: 0
Study 30770207 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practices for serious illness communication
Number of subjects: 0
Study 30770221 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine (120 μg) administered in various schedules (0-, 1-, 6-month; 0-, 2-, 6-month; 0-, 6-month; 0-, 2-month; or 0-, 4-month)
Number of subjects: 465
Study 30770221 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of MenB-FHbp vaccine administered 48 months after primary vaccination
Number of subjects: 465
Study 30770221 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluations during booster stage
Number of subjects: 465
Study 30770310 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa 5 mg/kg
Number of subjects: 24
Study 30770310 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa 10 mg/kg
Number of subjects: 24
Study 30770310 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa 20 mg/kg
Number of subjects: 24
Study 30770310 — intervention group
Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 24
Study 30770324 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based cART
Number of subjects: 141
Study 30770324 — intervention group
Group type: COMPARATOR
Intervention: Non-efavirenz-based cART
Number of subjects: 141
Study 30770348 — intervention group
Group type: EXPERIMENTAL
Intervention: Navoximod (GDC-0919) in combination with PD-L1 inhibitor Atezolizumab
Number of subjects: 0
Study 30770354 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine eye screening (visit 1)
Number of subjects: 906
Study 30770362 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression on myeloid cells
Number of subjects: 0
Study 30770362 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 expression on tumor cells
Number of subjects: 0
Study 30770362 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with macrophage gene expression
Number of subjects: 0
Study 30770362 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification
Number of subjects: 0
Study 30770394 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low VWF
Number of subjects: 110
Study 30770394 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (O blood group-matched)
Number of subjects: 110
Study 30770421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous brachial plexus PNS stimulation
Number of subjects: 11
Study 30770421 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study 30770528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (HR-HPV) testing with normal aLBC
Number of subjects: 426
Study 30770528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk human papillomavirus (HR-HPV) testing with low-grade SILs (LSILs)
Number of subjects: 426
Study 30770528 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of aLBC/HR-HPV testing
Number of subjects: 426
Study 30770534 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type influenza A(H3N2)2011 virus (106 TCID50)
Number of subjects: 37
Study 30770534 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type influenza A(H3N2)2011 virus (107 TCID50)
Number of subjects: 37
Study 30770534 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type influenza A(H3N2)2011 virus (any dose)
Number of subjects: 37
Study 30770543 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Serum Ferritin (SF)
Number of subjects: 234
Study 30770543 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 234
Study 30770543 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble Transferrin Receptor (sTfR)
Number of subjects: 234
Study 30770543 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin
Number of subjects: 234
Study 30770543 — intervention group
Group type: COMPARATOR
Intervention: IL-6 and CRP (inflammation markers)
Number of subjects: 234
Study 30770765 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic sclerosis (SSc) patients
Number of subjects: 480
Study 30770765 — intervention group
Group type: COMPARATOR
Intervention: Rheumatic diseases (SSc, RA, SLE, SjS)
Number of subjects: 480
Study 30770765 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher modified Rodnan skin scores (mRSS) in SSc patients
Number of subjects: 480
Study 30771036 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 311
Study 30771036 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 311
Study 30771200 — intervention group
Group type: EXPERIMENTAL
Intervention: DSF/Cu (disulfiram and copper) plus standard monthly temozolomide (TMZ) 80 mg PO TID and Cu 1.5 mg PO TID
Number of subjects: 23
Study 30771702 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (aboBoNT-A; Dysport®)
Number of subjects: 273
Study 30771794 — intervention group
Group type: EXPERIMENTAL
Intervention: DULK score, serum CRP, serum PCT
Number of subjects: 0
Study 30772227 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with preserved ejection fraction (HFpEF) subjects
Number of subjects: 140
Study 30772387 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk calculator
Number of subjects: 0
Study 30772387 — intervention group
Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 three-category score
Number of subjects: 0
Study 30772387 — intervention group
Group type: COMPARATOR
Intervention: COMPERA risk assessment strategy
Number of subjects: 0
Study 30772387 — intervention group
Group type: COMPARATOR
Intervention: FPHR risk assessment strategy
Number of subjects: 0
Study 30772588 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive training program for real-time optical diagnosis of colorectal polyps.
Number of subjects: 15
Study 30772821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation (CRFA)
Number of subjects: 67
Study 30772821 — intervention group
Group type: COMPARATOR
Intervention: Cooled radiofrequency ablation (CRFA) after intra-articular steroid injection (IAS)
Number of subjects: 67
Study 30772864 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination against five vaccine targets (pneumococcus, hepatitis B virus, etc.), specific details on dosage and duration not available.
Number of subjects: 0
Study 30772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified anthocyanins
Number of subjects: 0
Study 30772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild blueberries
Number of subjects: 0
Study 30772905 — intervention group
Group type: COMPARATOR
Intervention: Control drinks (fiber, minerals, vitamins)
Number of subjects: 0
Study 30772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily wild blueberry consumption for 1 month
Number of subjects: 0
Study 30772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanin plasma metabolites
Number of subjects: 0
Study 30772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of anthocyanin metabolites in mice
Number of subjects: 0
Study 30772905 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily wild blueberry consumption
Number of subjects: 0
Study 30772952 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients (n=52)
Number of subjects: 646
Study 30772952 — intervention group
Group type: COMPARATOR
Intervention: Non-migraine patients (n=594)
Number of subjects: 646
Study 30772952 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients with aura
Number of subjects: 646
Study 30773021 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of S-Adenosylhomocysteine Hydrolase (SAHH)
Number of subjects: 0
Study 30773021 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30773025 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 2287
Study 30773025 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 2287
Study 30773025 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of coronary arteries diseased
Number of subjects: 2287
Study 30773025 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of ischemia
Number of subjects: 2287
Study 30773077 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab combined with CHOP
Number of subjects: 0
Study 30773077 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30773100 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (4 g of eicosapentaenoic acid and docosahexaenoic acid daily)
Number of subjects: 17
Study 30773100 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study 30773118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment patients (Montreal Cognitive Assessment score <26) at baseline
Number of subjects: 298
Study 30773118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive decline (Montreal Cognitive Assessment score drop by ≥2 points) at 1 year
Number of subjects: 298
Study 30773118 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 298
Study 30773118 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent myocardial infarction
Number of subjects: 298
Study 30773459 — intervention group
Group type: EXPERIMENTAL
Intervention: HEU children
Number of subjects: 884
Study 30773459 — intervention group
Group type: COMPARATOR
Intervention: HU children
Number of subjects: 884
Study 30773463 — intervention group
Group type: EXPERIMENTAL
Intervention: BCL-2 inhibitor ABT-199
Number of subjects: 0
Study 30773463 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of heme biosynthesis
Number of subjects: 0
Study 30773970 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC support intervention
Number of subjects: 25
Study 30773970 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies used by IHCs
Number of subjects: 25
Study 30774324 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute chair rise test (3-minute CRT)
Number of subjects: 116
Study 30774324 — intervention group
Group type: EXPERIMENTAL
Intervention: DIRECT questionnaire
Number of subjects: 116
Study 30774324 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 116
Study 30774324 — intervention group
Group type: EXPERIMENTAL
Intervention: endurance exercise test
Number of subjects: 116
Study 30774388 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (Q8W, first three doses Q4W)
Number of subjects: 0
Study 30774388 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 4 weeks (Q4W)
Number of subjects: 0
Study 30774388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30774399 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT; antibiotics administered ≤48 hours post-initiation of antibiotic therapy)
Number of subjects: 385
Study 30774399 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT)
Number of subjects: 385
Study 30774635 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-based vaccines
Number of subjects: 0
Study 30774953 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Cox Model analysis of exacerbation risk factors
Number of subjects: 1247
Study 30774953 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry in primary care
Number of subjects: 1247
Study 30775698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rinse system (bottle A used in the morning for 4 weeks)
Number of subjects: 10
Study 30775698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rinse system (bottle B used in the evening for 8 weeks)
Number of subjects: 10
Study 30775698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rinse system (bottle A and B)
Number of subjects: 10
Study 30776019 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30776363 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 1.5 mg of paclitaxel
Number of subjects: 23
Study 30776452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d for 12 months
Number of subjects: 60
Study 30776920 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 in HFpEF
Number of subjects: 193
Study 30776920 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 in HFrEF
Number of subjects: 193
Study 30776920 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 in HFpEF and HFrEF
Number of subjects: 193
Study 30776994 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Guide Catheter (BGC)
Number of subjects: 445
Study 30776994 — intervention group
Group type: COMPARATOR
Intervention: Conventional Guide Catheter
Number of subjects: 445
Study 30776994 — intervention group
Group type: COMPARATOR
Intervention: Distal Access Catheter
Number of subjects: 445
Study 30777020 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding Self-Efficacy Scale to Measure Exclusive Breastfeeding (BSES-EBF)
Number of subjects: 477
Study 30777020 — intervention group
Group type: EXPERIMENTAL
Intervention: BSES-EBF Scale
Number of subjects: 477
Study 30777022 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 weekly group sessions called School of Health for Older People
Number of subjects: 0
Study 30777022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 30777022 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving the intervention)
Number of subjects: 0
Study 30777022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-utility analysis from a health system perspective
Number of subjects: 0
Study 30777049 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and exercise therapy (group-based program with 2 sessions of education and 8 weeks of supervised exercises)
Number of subjects: 0
Study 30777049 — intervention group
Group type: EXPERIMENTAL
Intervention: Education of clinicians (two-days course for physiotherapists and chiropractors)
Number of subjects: 0
Study 30777049 — intervention group
Group type: EXPERIMENTAL
Intervention: National level effects
Number of subjects: 0
Study 30777085 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference
Number of subjects: 447
Study 30777085 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 447
Study 30777085 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio
Number of subjects: 447
Study 30777448 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal smoke exposure
Number of subjects: 0
Study 30777448 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exposed to prenatal smoke)
Number of subjects: 0
Study 30777842 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge based on a pre-specified set of risk criteria
Number of subjects: 502
Study 30777842 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge management
Number of subjects: 502
Study 30777840 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-frail group
Number of subjects: 90
Study 30777840 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 90
Study 30777875 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (80 mg/m2)
Number of subjects: 139
Study 30778280 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS combined with Intensive Language-Action Therapy
Number of subjects: 0
Study 30778280 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30778345 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®])
Number of subjects: 0
Study 30778345 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30778520 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole followed by trastuzumab-pertuzumab for five cycles in molecular responders
Number of subjects: 64
Study 30778520 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel for 13 weeks combined with trastuzumab-pertuzumab in molecular non-responders
Number of subjects: 64
Study 30778520 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-enriched subtype in molecular responders
Number of subjects: 64
Study 30779631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake
Number of subjects: 0
Study 30779990 — intervention group
Group type: EXPERIMENTAL
Intervention: selonsertib
Number of subjects: 1667
Study 30780166 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.01, 0.05, 0.10 and 0.15 µg/kg/min; 15 minutes at each step)
Number of subjects: 10
Study 30781469 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioecological theory-based exercise facilitation contacts over 50 weeks
Number of subjects: 449
Study 30781469 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 449
Study 30782111 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of attitudes (21 items, alpha = 0.84)
Number of subjects: 1964
Study 30782111 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of perceived behavioral control (10 items, alpha = 0.85)
Number of subjects: 1964
Study 30782111 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of subjective norms (9 items, alpha = 0.89)
Number of subjects: 1964
Study 30782111 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model fit
Number of subjects: 1964
Study 30782342 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake-regional anaesthesia
Number of subjects: 722
Study 30782342 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 722
Study 30782413 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 0
Study 30782413 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 0
Study 30782509 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral obesity assessed by VFA
Number of subjects: 229
Study 30782509 — intervention group
Group type: COMPARATOR
Intervention: Central obesity measured by WC
Number of subjects: 229
Study 30782589 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAD Longitudinal Cohort Study (LCS)
Number of subjects: 0
Study 30782611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and fludarabine lymphodepletion followed by CD19 CAR T cells
Number of subjects: 0
Study 30782670 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis
Number of subjects: 505
Study 30782684 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 370
Study 30782698 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy device (cold and vibration)
Number of subjects: 346
Study 30782698 — intervention group
Group type: COMPARATOR
Intervention: Liposomal lidocaine 4% cream (topical anaesthetic)
Number of subjects: 346
Study 30782707 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortnightly finger prick capillary blood sampling
Number of subjects: 400
Study 30782707 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of stool samples and vaginal swabs each trimester, at delivery and postpartum
Number of subjects: 400
Study 30782707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested case-control analysis comparing perturbations of transcript abundance in capillary blood
Number of subjects: 400
Study 30782707 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA profiles of circulating, non-coding RNA in cord blood serum
Number of subjects: 400
Study 30782707 — intervention group
Group type: EXPERIMENTAL
Intervention: Placenta tissue of preterm and term neonates
Number of subjects: 400
Study 30782737 — intervention group
Group type: EXPERIMENTAL
Intervention: National Early Warning Score (NEWS) alone
Number of subjects: 1303
Study 30782737 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS combined with inflammatory markers (WCC, PCT, MR-proADM)
Number of subjects: 1303
Study 30782737 — intervention group
Group type: COMPARATOR
Intervention: NEWS alone
Number of subjects: 1303
Study 30782744 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related comorbidities (ARCs)
Number of subjects: 1415
Study 30782749 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-based workshop intervention for increasing bouted MVPA
Number of subjects: 48
Study 30782749 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly emails and monthly phone calls for 3 months
Number of subjects: 48
Study 30782749 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments at baseline, 3 months, and 6 months
Number of subjects: 48
Study 30782760 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Young Children (intervention)
Number of subjects: 120
Study 30782892 — intervention group
Group type: EXPERIMENTAL
Intervention: Community level intervention for pre-eclampsia led by community health workers
Number of subjects: 9172
Study 30782892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary least squares model
Number of subjects: 9172
Study 30782924 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor trauma care delivered in a general practice
Number of subjects: 200